Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
The gross proceeds from the offering are expected to be approximately
The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of an automatically effective registration statement. A final prospectus supplement related to the offering will be filed with the
This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Any statements in this press release about the Company’s future expectations, plans and prospects, including statements regarding the offering, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “future”, “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the potential completion of the offering, satisfaction of customary closing conditions related to the offering, those related to the actual and expected effects of the COVID-19 pandemic, other macro-economic events and related response measures on the Company’s business and operations, the timing, costs, conduct and outcome of the Company’s ongoing and planned research and preclinical development activities and clinical trials, the Company’s ability to establish and maintain capabilities and capacity for the manufacture of its product candidates, the Company’s competitive position, the Company’s expectations regarding the market dynamics for treatments for GA and other commercial matters, the Company’s personnel and human capital resources, need for, and ability to obtain, additional financing, plans and ability to consummate business development transactions, whether the Company’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital requirements on its expected timelines, and other factors discussed in the “Risk Factors” section contained in the preliminary prospectus supplement and the reports that the Company files with the
Senior Vice President, Investor Relations